Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Radium-223 for Treatment of Prostate Cancer

February 13th 2015

Antiandrogen Resistance With AR-V7 in CRPC

February 13th 2015

Enzalutamide Offers Second Option in Pre-Chemo CRPC

February 13th 2015

Pre-Chemotherapy Abiraterone Acetate in CRPC

February 13th 2015

Integrating CHAARTED Findings Into Prostate Cancer Care

February 13th 2015

CHAARTED Trial Changes Practice in Prostate Cancer

February 13th 2015

ADT in Prostate Cancer: Agonists Versus Antagonists

February 13th 2015

Integrating Molecular Testing Into Urology Practices

February 13th 2015

Biomarkers for Aiding Risk Stratification and Treatment Decisions

February 13th 2015

Follow-up Biomarker Testing in Prostate Cancer

February 13th 2015

Strategies for Using Biomarkers in Prostate Cancer

February 13th 2015

Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

February 10th 2015

Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

Dr. Mark Delworth on Robotic Prostatectomy

February 9th 2015

Mark Delworth, MD, a urologist and the medical director of the Minimally Invasive and Robotic Surgery Program at TriHealth Hospital, talks about the outcomes of robotic surgery for the treatment of prostate cancer.

Clinical and Economic Impact of Gene Expression Testing in Localized Prostate Cancer

February 4th 2015

Biopsy-based cell cycle progression gene expression testing can aid in the stratification of patients with localized prostate cancer based on disease aggressiveness.

Latest News & Insight: January 31, 2015

January 31st 2015

Dr. Taneja on MRI for Prostate Cancer Detection

January 30th 2015

Samir Taneja, MD, professor of Urology and Radiology and director of the Division of Urologic Oncology at NYU Langone Medical Center.

Dr. Tward on Abbreviated Course ADT for Prostate Cancer

January 23rd 2015

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

Two Studies Explore Role of Radiation, Bisphosphonates in Prostate Cancer Care

January 19th 2015

For older men with prostate cancer, adding radiation to hormone therapy is both tolerable and effective in reducing the number of deaths.

Dendreon Revenue Rises, Despite Restructuring

January 14th 2015

Increased utilization of the autologous cellular immunotherapy sipuleucel-T (Provenge) led to a $20.1 million improvement in total revenue in 2014 for the manufacturer Dendreon, when compared with 2013.

Should a Lower-Grade Prostate Tumor Be Called Cancer?

January 9th 2015

For some insight on this discussion, OncLive sat down with prostate cancer expert and president-elect of SUO, Leonard G. Gomella, MD.